DE000A11QW50 (XETR)
Epigenomics AG Share
No Price
Performance
Day | Week | Month | 3 Months | 6 Months | 1 Year | 5 Years |
---|---|---|---|---|---|---|
- | - | 0,00 % | 0,00 % | 0,00 % | -65,00 % | -99,68 % |
Company Profile for Epigenomics AG Share
Epigenomics AG, a molecular diagnostics company, focuses on liquid biopsy for the early detection of cancer. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer in the United States, Europe, and China. The company's products also include hepatocellular carcinoma blood test; Epi proColon, a liquid biopsy test for detection of colorectal cancer; and Epi BiSKit, a pre-analytical tool, which provides a set of reagents for the preparation of bisulfite-converted DNA. Its research and development activities identify suitable biomarkers in human tissue and developing and patenting the corresponding in vitro diagnostic blood tests. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany.
Company Data for Epigenomics AG Share
Name Epigenomics AG
Company Epigenomics AG
Website https://www.epigenomics.com
Primary Exchange
XETRA
ISIN DE000A11QW50
Asset Class Share
Sector Healthcare
Industry Medical - Diagnostics & Research
CEO Dr. Noel Thomas Doheny
Country Germany
Currency EUR
Employees 0,0 T
Address Geneststrasse 5, 10829 Berlin
IPO Date 2004-07-19
Ticker Symbols
Name | Symbol |
---|---|
XETRA | ECX.DE |
More Shares
Investors who Epigenomics AG hold also have the following shares in their portfolio:
The financial platform MoneyPeak tracks and analyzes investments and portfolios.
From securities portfolios to crypto purchases.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.
Useful, simple, and free. Stocks, ETFs, ETCs, ETNs, indices, funds, bonds, certificates, currencies, options, rights issue.